Skip Navigation LinksHome > February 2010 - Volume 21 - Issue 2 > Good response to second-line bevacizumab and interferon-α in...
Text sizing:
A
A
A
Anti-Cancer Drugs:
doi: 10.1097/CAD.0b013e3283340d1f
Case Reports

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; Zovato, Stefania; Donach, Martin; Nicoletto, Ornella; Farina, Miriam; Furini, Lara; Ceravolo, Renato; Carli, Paolo; Lombardi, Giuseppe

Collapse Box

Abstract

In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-α in a patient who failed classical sunitinib treatment.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.